Suppr超能文献

尿液 CD80 作为肾脏疾病患者诊断标志物的效用。

The utility of urinary CD80 as a diagnostic marker in patients with renal diseases.

机构信息

Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.

Sysmex Corporation, Technology Development, Elemental Technology Development 2, Kobe, Japan.

出版信息

Sci Rep. 2018 Nov 23;8(1):17322. doi: 10.1038/s41598-018-35798-2.

Abstract

CD80, which regulates T cell activation, may provide a differential diagnostic marker between minimal change disease (MCD) and other renal diseases, including focal segmental glomerular sclerosis (FSGS). However, recent reports show contrasting results. Therefore, we evaluated the utility of urinary CD80 as a diagnostic biomarker. We collected 65 urine samples from 55 patients with MCD (n = 31), FSGS (n = 4), inherited nephrotic syndrome (n = 4), Alport syndrome (n = 5) and other glomerular diseases (n = 11), and control samples (n = 30). We measured urinary CD80 levels by ELISA. Urinary CD80 (ng/gCr) (median, interquartile range) levels were significantly higher in patients with MCD in relapse (91.5, 31.1-356.0), FSGS (376.2, 62.7-1916.0), and inherited nephrotic syndrome (220.1, 62.9-865.3), than in patients with MCD in remission (29.5, 21.7-52.8) (p < 0.05). Elevation of urinary CD80 was observed, even in patients with inherited nephrotic syndrome unrelated to T cell activation. Additionally, urinary CD80 was positively correlated with urinary protein levels. Our results suggest that urinary CD80 is unreliable as a differential diagnostic marker between MCD in relapse and FSGS or inherited kidney diseases. Increased urinary CD80 excretion was present in all patients with active kidney disease.

摘要

CD80 可调节 T 细胞的激活,可能为微小病变性肾病(MCD)和包括局灶节段性肾小球硬化(FSGS)在内的其他肾脏疾病提供一个有差异的诊断标志物。然而,最近的报告显示结果相反。因此,我们评估了尿 CD80 作为诊断生物标志物的效用。我们收集了 55 例 MCD 患者(n=31)、FSGS(n=4)、遗传性肾病综合征(n=4)、Alport 综合征(n=5)和其他肾小球疾病(n=11)以及对照样本(n=30)的 65 份尿样。我们通过 ELISA 法测定尿 CD80 水平。复发期 MCD(91.5,31.1-356.0)、FSGS(376.2,62.7-1916.0)和遗传性肾病综合征(220.1,62.9-865.3)患者的尿 CD80(ng/gCr)水平(中位数,四分位间距)显著高于缓解期 MCD 患者(29.5,21.7-52.8)(p<0.05)。即使在与 T 细胞激活无关的遗传性肾病综合征患者中,也观察到尿 CD80 的升高。此外,尿 CD80 与尿蛋白水平呈正相关。我们的结果表明,尿 CD80 不可靠,不能作为复发期 MCD 与 FSGS 或遗传性肾病之间的差异诊断标志物。所有活动性肾病患者均有增加的尿 CD80 排泄。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f5c/6251900/f3e349a969bf/41598_2018_35798_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验